Research programme: protein therapeutics - Complix

Drug Profile

Research programme: protein therapeutics - Complix

Alternative Names: Alphabodies; Alphabody; Anti-MCL1 alphabody; Cell-penetrating alphabodies; CMPX 1023; CMX-02; CPABs - Complix

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Complix
  • Class Antineoplastics; Antivirals; Proteins
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Interleukin 23 inhibitors; MCL1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders; CNS disorders; Metabolic disorders; Viral infections

Most Recent Events

  • 20 Sep 2018 Protein therapeutics - Complix is available for licensing as of 20 Sep 2018.
  • 19 Dec 2017 Comlpix has patent protection for Alphabody™platform and Cell Penetrating Alphabodies™
  • 29 Nov 2016 Protein therapeutics are still in preclinical trials for Cancer in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top